Eddie Reed, MD; Joan Jacob, RN, MSN
This content is PDF only. Please click on the PDF icon to access.
To the Editor: Carboplatin
is a second-generation platinum analogue that has activity in refractory ovarian cancer similar to that of cisplatin (1). Carboplatin appears to have a spectrum of clinical toxicity different from that of cisplatin: at therapeutically equivalent doses, the dose-limiting toxicity for carboplatin is myelosuppression, with comparatively little renal or neurologic toxicity (1-3). For this reason, we have begun to study the use of high-dose carboplatin therapy (800 mg/m2 body surface area · cycle) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with refractory ovarian cancer. It is anticipated that GM-CSF may blunt carboplatin-induced bone marrow suppression,
Reed E, Jacob J. Carboplatin and Renal Dysfunction. Ann Intern Med. 1989;110:409. doi: 10.7326/0003-4819-110-5-409_1
Download citation file:
Published: Ann Intern Med. 1989;110(5):409.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use